For laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice, and no product is intended to diagnose, treat or prevent any condition.
IGF-1 LR3 Side Effects Observed in Research
This page summarises the adverse findings that published studies report for IGF-1 and its analogues, including IGF-1 LR3, and explains what they mean for designing and interpreting laboratory and animal research. It is not medical information. IGF-1 LR3 is not a licensed medicine and Peptides Lab UK supplies it for laboratory research use only.
Where does the safety evidence come from?
There are almost no controlled human studies of IGF-1 LR3 itself. Most of what is known comes from three sources:
- Animal studies of IGF-1 analogues, including the original work on LR3 and des(1-3)IGF-1 in rats and pigs (Francis et al., J Mol Endocrinol 1992; Walton et al., 1995).
- Clinical data on mecasermin, recombinant native IGF-1, which is a licensed medicine for a rare growth disorder in some countries. Its reported adverse effects give the best guide to what IGF-1 receptor activation can do in a whole organism (Rosenbloom, Adv Ther 2009).
- Mechanistic knowledge of IGF-1 receptor signalling from cell biology.
Because LR3 escapes IGF-binding proteins, findings for native IGF-1 cannot be transferred directly; they indicate which effects to look for, not their size.
Hypoglycaemia (low blood glucose)
The most consistently reported adverse effect of IGF-1 receptor activation is a fall in blood glucose. IGF-1 shares structure and signalling with insulin and can increase glucose uptake into muscle and other tissues; it can also act on the insulin receptor at higher concentrations. Hypoglycaemia is the most commonly reported adverse effect in mecasermin clinical experience (Rosenbloom, Adv Ther 2009). For animal studies with IGF-1 analogues, this means blood glucose monitoring is an essential safety and data-quality measure, and feeding state must be standardised and recorded.
Fluid retention and tissue swelling
Growth factor signalling through the GH/IGF-1 axis is associated with sodium and water retention. Clinical reports for IGF-1 therapy include oedema and, less often, raised intracranial pressure. In animal work, body weight changes should therefore be interpreted carefully: an increase may reflect fluid rather than tissue mass, so body composition methods are better than weight alone.
Lymphoid tissue growth and tonsillar enlargement
Lymphoid tissue hypertrophy, including tonsillar enlargement, is among the effects reported with IGF-1 therapy. This illustrates that IGF-1R signalling stimulates growth in many tissues, not only muscle. In animal models, organ weights at necropsy are a sensible secondary readout.
Growth-promoting signals and tumour biology
IGF-1R activates PI3K/Akt/mTOR and MAPK pathways that drive cell proliferation and inhibit apoptosis. That is why IGF-1 signalling is widely studied in cancer biology, and why the theoretical concern of promoting the growth of existing abnormal cells is raised in reviews. For researchers, this means:
- Proliferation readouts in cell lines should be interpreted with the cell type’s oncogenic background in mind.
- Long-term animal studies should include histopathology of relevant tissues.
Local tissue reactions in animal studies
Local tissue reactions and lipohypertrophy are reported with repeated local delivery of IGF-1 in clinical use. In animal models, rotating the delivery site and examining local tissue is part of good practice, and vehicle controls must use the same route.
Effects reported less consistently
Several other effects appear in clinical reports for IGF-1 therapy or in animal studies, but less consistently. They include headache, joint and muscle aches, coarsening of facial features with long-term use, and changes in lipid profiles. Some may relate to fluid retention or to growth of soft tissues. Their size and frequency vary widely between reports and populations, and many reports are uncontrolled. For research purposes, they are best treated as signals to monitor rather than established effects of IGF-1 LR3 specifically.
How this differs from growth hormone
Growth hormone raises IGF-1 but also has its own direct effects, including on fat breakdown and on glucose, where GH tends to raise blood glucose while IGF-1 tends to lower it. Studies that compare GH-axis peptides with IGF-1 analogues therefore often see opposite effects on glucose. Keeping this in mind avoids attributing a glucose change to the wrong part of the axis. For a fuller comparison, see IGF-1 LR3 vs HGH.
How adverse findings affect study design
| Reported finding | What to measure or control |
|---|---|
| Hypoglycaemia | Blood glucose at defined time points; standardised feeding state |
| Fluid retention | Body composition, not just body weight |
| Tissue growth | Organ weights and histology |
| Insulin receptor cross-reactivity | Insulin receptor phosphorylation; IGF-1R inhibitor controls |
| Local tissue reactions | Route-matched vehicle controls; local histology |
Effects on the GH/IGF-1 feedback loop
IGF-1 normally feeds back to the pituitary and hypothalamus to reduce growth hormone release. Adding an IGF-1 analogue to an animal model can therefore lower endogenous GH secretion. This matters for interpretation: an outcome in an IGF-1 LR3 study reflects both the analogue itself and the change in the animal’s own GH and IGF-1. Measuring endogenous GH, total IGF-1 and IGFBP-3 helps separate these effects, although assays for IGF-1 may cross-react with analogues, so check the assay’s specificity.
Cell culture findings that look like adverse effects
Some effects reported in cell studies are better described as expected pharmacology than as toxicity. Examples include increased proliferation in many cell types, reduced apoptosis after stress, and changes in glucose uptake. These become problems only when they confound the question being studied, for example when a proliferation effect hides a differentiation readout. Planning for them, with the right controls and readouts, avoids misinterpreting results.
Why findings vary between studies
- Analogue differences. LR3, DES and native IGF-1 differ in IGFBP binding and clearance.
- Species. IGFBP profiles and glucose regulation differ between rodents, pigs and humans.
- Exposure. Most effects are concentration-dependent, and the same nominal amount can give very different exposure depending on route and formulation.
- Purity. Impurities or endotoxin can produce effects unrelated to IGF-1R. Check purity and identity on the batch certificate; see how to read a COA.
Reporting adverse findings in your own studies
Good reporting makes safety findings useful to others. Record the analogue, batch and purity; the species, strain, sex and age of animals; the route, timing and duration of exposure; feeding state; and every adverse observation, including those judged unrelated. Report glucose results with the time since the last feed, and report body composition rather than body weight alone where possible. Following the ARRIVE guidelines for animal research is a practical way to make sure nothing important is left out, and makes it easier for later reviews to pool findings across studies.
Related laboratory guides
For structure and receptor pharmacology, see IGF-1 LR3 vs IGF-1 DES and IGF-1 LR3 vs HGH. For handling, see the IGF-1 LR3 storage and handling guide. All our batches are HPLC & COA Verified; see our quality standards SOP.
Frequently asked questions
What adverse effects are reported for IGF-1 in studies?
The most consistently reported is hypoglycaemia. Others reported with IGF-1 therapy include fluid retention, lymphoid tissue enlargement and local tissue reactions.
Is there human safety data for IGF-1 LR3?
There is very little controlled human data for IGF-1 LR3. Most evidence comes from animal studies of IGF-1 analogues and clinical data on recombinant native IGF-1 (mecasermin).
Why does IGF-1 lower blood glucose?
IGF-1 is structurally related to insulin, increases glucose uptake into tissues and can activate the insulin receptor at higher concentrations.
What should animal studies with IGF-1 analogues monitor?
Blood glucose, body composition, organ weights and histology, alongside route-matched vehicle controls.
References
- Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009.
- Francis GL et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 1992.
- Walton PE et al. In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness. Prog Growth Factor Res 1995.
